Published in Breast Cancer Res Treat on June 14, 2011
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh Migr (2012) 1.41
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res (2014) 1.17
Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res (2014) 1.09
Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2014) 1.07
Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One (2012) 1.06
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol (2015) 1.05
Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One (2012) 1.03
The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer (2013) 1.00
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Front Immunol (2015) 0.96
Clinical and biological implications of the tumor microenvironment. Cancer Microenviron (2012) 0.95
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 0.91
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med (2015) 0.88
The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC Cancer (2013) 0.88
High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther (2014) 0.88
Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol (2013) 0.88
Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One (2012) 0.87
Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology (2015) 0.87
Stromal biomarkers in breast cancer development and progression. Clin Exp Metastasis (2012) 0.86
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology (2015) 0.86
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.84
CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology (2012) 0.83
CD33⁺/p-STAT1⁺ double-positive cell as a prognostic factor for stage IIIa gastric cancer. Med Oncol (2013) 0.82
Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. Adv Cancer Res (2015) 0.80
Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget (2015) 0.80
Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers. Cancers (Basel) (2014) 0.80
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. PLoS Biol (2015) 0.78
The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer. World J Surg Oncol (2014) 0.78
Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One (2014) 0.78
Adaptive immunity programmes in breast cancer. Immunology (2016) 0.77
Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. Mol Cell Pharmacol (2013) 0.77
Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer (2015) 0.77
Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol (2014) 0.76
Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma. Hepatobiliary Surg Nutr (2014) 0.76
Towards tumor immunodiagnostics. Ann Transl Med (2016) 0.75
Immune DNA signature of T-cell infiltration in breast tumor exomes. Sci Rep (2016) 0.75
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. Oncoimmunology (2017) 0.75
Distribution and significance of interstitial fibrosis and stroma-infiltrating B cells in tongue squamous cell carcinoma. Oncol Lett (2016) 0.75
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med (2016) 0.75
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat (2016) 0.75
Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. Front Immunol (2016) 0.75
Prognostic potential of an immune score based on the density of CD8(+) T cells, CD20(+) B cells, and CD33(+)/p-STAT1(+) double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients. Chin J Cancer Res (2016) 0.75
The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS One (2016) 0.75
Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J Cancer Res Clin Oncol (2017) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Cross-cultural primary care: a patient-based approach. Ann Intern Med (1999) 5.06
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol (1970) 4.48
Analysis of vertebrate SCL loci identifies conserved enhancers. Nat Biotechnol (2000) 4.01
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Ecstasy and neurodegeneration. BMJ (1996) 2.93
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer. Br J Surg (1989) 2.84
Total synthesis of a human leukocyte interferon gene. Nature (1981) 2.76
How to improve plastic surgery knowledge, skills and career interest in undergraduates in one day. J Plast Reconstr Aesthet Surg (2009) 2.54
The SCL gene specifies haemangioblast development from early mesoderm. EMBO J (1998) 2.47
Autologous fat transfer--a review of the literature with a focus on breast cancer surgery. J Plast Reconstr Aesthet Surg (2008) 2.40
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer (2001) 2.16
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol (1972) 2.05
Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res (2001) 2.04
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer (2004) 1.97
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol (2005) 1.96
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer (2007) 1.94
Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology (1995) 1.90
Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol (2000) 1.88
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
Reading the prognosis of the individual with breast cancer. Eur J Cancer (2007) 1.83
Screening interval breast cancers: mammographic features and prognosis factors. Radiology (1996) 1.82
Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. BMJ (1993) 1.79
Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology (1994) 1.78
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol (2011) 1.73
An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics (2002) 1.73
X-ray refraction effects: application to the imaging of biological tissues. Br J Radiol (2003) 1.73
A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology (1984) 1.72
Analysis of pineal and brain indole alkylamines by gas chromatography-mass spectrometry. Adv Biochem Psychopharmacol (1973) 1.71
Cytological grading of breast carcinoma--a feasible proposition? Cytopathology (1990) 1.70
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature (1968) 1.69
An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development (1999) 1.67
Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer (2007) 1.66
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
The SCL gene: from case report to critical hematopoietic regulator. Blood (1999) 1.65
The impact of core-biopsy on pre-operative diagnosis rate of screen detected breast cancers. Clin Radiol (1996) 1.64
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer (1995) 1.60
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol (2009) 1.60
Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen (2001) 1.58
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood (2000) 1.58
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology (2007) 1.57
Early-onset breast cancer--histopathological and prognostic considerations. Br J Cancer (1997) 1.56
Cephalosporin-induced immune neutropenia. Br J Haematol (1985) 1.56
The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch (2008) 1.55
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
Therapeutic mammaplasty for centrally located breast tumors. Plast Reconstr Surg (2006) 1.55
Consistency of histopathological reporting of breast lesions detected by screening: findings of the U.K. National External Quality Assessment (EQA) Scheme. U. K. National Coordinating Group for Breast Screening Pathology. Eur J Cancer (1994) 1.54
Helix pomatia and Ulex europeus lectin binding in human breast carcinoma. J Pathol (1987) 1.54
Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer (1998) 1.51
Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg (2003) 1.50
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) - an alternative to surgery in selected cases. Breast (2008) 1.48
Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol (2005) 1.48
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Method for grading breast cancer. J Clin Pathol (1993) 1.46
Environmental impacts and sustainability of egg production systems. Poult Sci (2011) 1.46
Transverse Upper Gracilis (TUG) flap for volume replacement in breast conserving surgery for medial breast tumours in small to medium sized breasts. J Plast Reconstr Aesthet Surg (2011) 1.45
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1985) 1.43
Density of lymphocytic infiltration of primary breast cancer does not affect short-term disease-free interval or survival. J R Coll Surg Edinb (1990) 1.41
Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol (2011) 1.41
Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. Br J Surg (2001) 1.41
The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochem Pharmacol (1970) 1.41
Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev Biol (1999) 1.41
The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer (1998) 1.40